PrimeC has been given an ‘Orphan Drug’ status by the FDA (Food and Drug Administration) and EMA (European Medicines Agency).
The first patient with small cell lung cancer has been dosed in a trial of peluntamig (PT217) combined with chemotherapy.
The Orphan Drugs Market is experiencing significant growth due to increasing investment in rare disease research, regulatory incentives, and advancements in biotechnology. Orphan drugs are specialized ...
| Avoid common pitfalls in EU orphan drug market access—learn how local expertise can help navigate pricing, reimbursement, ...
As we observe Rare Disease Day today, let us take a look at seven drugs poised to be approved to address rare diseases in ...
US-based clinical-stage company Sterotherapeutics has announced the commencement of a Phase II clinical trial for its drug ...
TNG462 granted Orphan Drug Designation for treatment of pancreatic cancer –– Investigational New Drug (IND) application for TNG456, a ...
February 28, 2025 (Investorideas.com Newswire) Investorideas.com, a global news source and expert investing resource, ...
Hosted on MSN3d
Neurotech receives positive opinion for orphan status in Rett Syndrome from European drug regulatorNeurotech has received positive feedback from the European Medicines Agency (EMA) on its orphan drug application for NTI164 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback